Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

Editas Medicine (Nasdaq: EDIT) has announced plans to seek a partner or buyer for its lead CRISPR program, reni-cel, as the ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

The global CRISPR and Cas Gene Market was valued at USD 1.8 billion in 2021. With an impressive projected growth rate of 30.2 ...